Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2014

01-07-2014 | Research

Tumor-Associated Macrophages are Correlated with Tamoxifen Resistance in the Postmenopausal Breast Cancer Patients

Authors: Qi-jia Xuan, Jing-xuan Wang, Abiyasi Nanding, Zhi-peng Wang, Hang Liu, Xin Lian, Qing-yuan Zhang

Published in: Pathology & Oncology Research | Issue 3/2014

Login to get access

Abstract

Tumor-associated macrophages (TAMs) have been correlated with increased angiogenesis and poor prognosis in breast cancer. However, the precise role of TAMs in tamoxifen resistance remains unclear. We used immunohistochemical method to examine the expression of epidermal growth factor receptor (EGFR) and CD163+ macrophages in 100 breast cancer tissues. The clinical and biological features of 100 patients were estrogen receptor (ER)-positive and human epidermal growth factor receptor 2(Her-2)-negative tumors. The tamoxifen resistant tissues (n = 48) were the surgical excision samples from patients who developed recurrence or metastasis at the time of adjuvant tamoxifen treatment. The tamoxifen resistant tissues were contrast to tamoxifen sensitive tissues (n = 52). Positive staining for EGFR and CD163+ macrophages were observed in 21 samples (43.8 %) and in 26 samples (54.2 %) respectively in tamoxifen resistance group, which were higher than that of tamoxifen sensitive group (P = 0.001 and P = 0.000279 respectively). Significant positive correlations were found between the expression of EGFR and CD163+ macrophages (r = 0.567, P < 0.01). CD163+ macrophages were positively correlated with tumor size, lymph node metastasis and obesity. Obesity was also related to tamoxifen resistance (P < 0.05). The patients with higher density of CD163+ macrophages infiltration suffered from shorter time to develop recurrence or metastasis (P < 0.05). TAMs may be associated with tamoxifen resistance. Further studies are needed to investigate the potential mechanism between TAMs and tamoxifen resistance.
Literature
1.
2.
Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631–643PubMedCrossRef
3.
4.
5.
Beelen K, Zwart W, Linn SC (2012) Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol 9:529–541PubMedCrossRef
6.
7.
8.
9.
Sica A, Schioppa T, Mantovani A et al (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42:717–727PubMedCrossRef
10.
Mantovani A, Sica A, Sozzani S et al (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686PubMedCrossRef
11.
Lau SK, Chu PG, Weiss LM (2004) CD163 A specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 122:794–801PubMedCrossRef
12.
Leek RD, Harris AL (2002) Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7:177–189PubMedCrossRef
13.
Soeda S, Nakamura N, Ozeki T et al (2008) Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol 109:122–128PubMedCrossRef
14.
Konecny GE, Santos L, Winterhoff B et al (2008) HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 100:89–95PubMedCentralPubMedCrossRef
15.
García-Becerra R, Santos N, Díaz L et al (2012) Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 14:108–145PubMedCentralPubMedCrossRef
16.
McKenna NJ, Lanz RB, O’Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321–344PubMed
17.
Frasor J, Danes JM, Komm B et al (2003) Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinol 144:4562–4574CrossRef
18.
19.
Norris JD, Fan D, Kerner SA et al (1997) Identification of a third autonomous activation domain within the human estrogen receptor. Mol Endocrinol 11:747–754PubMedCrossRef
20.
Nicholson RI, Hutcheson IR, Knowlden JM et al (2004) Nonendocrine pathways and endocrine resistance observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10:346s–354sPubMedCrossRef
21.
Arpino G, Green SJ, Allred DC et al (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer a southwest oncology group study. Clin Cancer Res 10:5670–5676PubMedCrossRef
22.
Tang X (2013) Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett
23.
Volodko N, Reiner A, Rudas M et al (1998) Tumour-associated macrophages in breast cancer and their prognostic correlations. Breast 7:99–105CrossRef
24.
Mahmoud SMA, Lee AHS, Paish EC et al (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65:159–163PubMedCrossRef
25.
Morris PG, Hudis CA, Giri D et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 4:1021–1029CrossRef
26.
27.
Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defınes macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355PubMedCrossRef
28.
Zhao Y, Agarwal VR, Mendelson CR et al (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739–5742PubMed
29.
Irahara N, Miyoshi Y, Taguchi T et al (2006) Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int J Cancer 118:1915–1921PubMedCrossRef
30.
Bachelot T, Ray-Coquard I, Menetrier-Caux C et al (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721–1726PubMedCentralPubMedCrossRef
31.
Dandona P, Weinstock R, Thusu K et al (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907–2910PubMed
32.
Leek RD, Hunt NC, Landers RJ et al (2000) Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190:430–436PubMedCrossRef
33.
Yang J, Liao D, Chen C et al (2013) Tumor associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 31:248–258PubMedCrossRef
34.
Vlaicu P, Mertins P, Thomas M et al (2013) Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer 13:197PubMedCentralPubMedCrossRef
35.
Condeelis J, Segall JE (2003) Intravital imaging of cell movement in tumours. Nat Rev Cancer 3:921–930PubMedCrossRef
Metadata
Title
Tumor-Associated Macrophages are Correlated with Tamoxifen Resistance in the Postmenopausal Breast Cancer Patients
Authors
Qi-jia Xuan
Jing-xuan Wang
Abiyasi Nanding
Zhi-peng Wang
Hang Liu
Xin Lian
Qing-yuan Zhang
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-013-9740-z

Other articles of this Issue 3/2014

Pathology & Oncology Research 3/2014 Go to the issue

Research

Altered Expression of Multiple Genes Involved in Retinoic Acid Biosynthesis in Human Colorectal Cancer

Research

A ‘Waterfall’ Transfer-based Workflow for Improved Quality of Tissue Microarray Construction and Processing in Breast Cancer Research

Research

Confocal Microscopy of Epithelial and Langerhans Cells of the Cornea in Patients Using Travoprost Drops Containing Two Different Preservatives

Research

Hodgkin Disease Therapy Induced Second Malignancy Susceptibility 6q21 Functional Variants in Roma and Hungarian Population Samples

Research Paper

Accurate Determination of the Pathological Stage with Gross Dissection Protocol for Radical Cystectomy

Research

Possible Prognostic Value of BORIS Transcript Variants Ratio in Laryngeal Squamous Cell Carcinomas – a Pilot Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits